Indication
SOX
1 clinical trial
1 product
Clinical trial
A Single-arm, Multicenter, Open-label Phase II Study of Fruquintinib Plus SOX as a Neoadjuvant Therapy for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-11-05
Product
Fruquintinib + SOX